BRPI1010120A2 - composição de surfactante reconstituído melhorada contendo análogos de proteína b do surfactante (sp-b) e proteína c do surfactante ( sp-c) - Google Patents

composição de surfactante reconstituído melhorada contendo análogos de proteína b do surfactante (sp-b) e proteína c do surfactante ( sp-c)

Info

Publication number
BRPI1010120A2
BRPI1010120A2 BRPI1010120-9A BRPI1010120A BRPI1010120A2 BR PI1010120 A2 BRPI1010120 A2 BR PI1010120A2 BR PI1010120 A BRPI1010120 A BR PI1010120A BR PI1010120 A2 BRPI1010120 A2 BR PI1010120A2
Authority
BR
Brazil
Prior art keywords
surfactant
protein
analogs
composition containing
surfactant protein
Prior art date
Application number
BRPI1010120-9A
Other languages
English (en)
Inventor
Pivetti Fausto
Bocchi Monica
Soliani Raschini Annamaria
Original Assignee
Chiesi Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41055357&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1010120(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farmaceutici S.P.A. filed Critical Chiesi Farmaceutici S.P.A.
Publication of BRPI1010120A2 publication Critical patent/BRPI1010120A2/pt
Publication of BRPI1010120B1 publication Critical patent/BRPI1010120B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/395—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0082—Lung surfactant, artificial mucus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Cosmetics (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)

Abstract

composição surfactante reconstituída melhorada contendo análogos de proteína 8 do surfactante (sp-8) e proteína c do surfactante (sp-c) a presente invenção refere-se a um surfactante pulmonar reconstituído, compreendendo urn carregador lipídico, üma combinação de análogo de peptfdeo da proteína nativa do surfactante sp-c com um análogo de polipeptídeo particular da proteína nativa do surfactante sp-b. a invenção também refere-se às formulações farmacêuticas desta e a seu uso para o tratamento ou profilaxia de sdr e outros distúrbios respiratórios.
BRPI1010120-9A 2009-06-05 2010-05-31 Composição surfactante reconstituída melhorada contendo análogos de proteína b do surfactante (sp-b) e proteína c do surfactante (sp-c) BRPI1010120B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09162052 2009-06-05
IT09162052.6 2009-06-05
PCT/EP2010/003293 WO2010139442A1 (en) 2009-06-05 2010-05-31 Improved reconstituted surfactant composition containing analogs of surfactant protein b (sp-b) and surfactant protein c (sp-c)

Publications (2)

Publication Number Publication Date
BRPI1010120A2 true BRPI1010120A2 (pt) 2019-03-26
BRPI1010120B1 BRPI1010120B1 (pt) 2022-12-06

Family

ID=41055357

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1010120-9A BRPI1010120B1 (pt) 2009-06-05 2010-05-31 Composição surfactante reconstituída melhorada contendo análogos de proteína b do surfactante (sp-b) e proteína c do surfactante (sp-c)

Country Status (35)

Country Link
US (1) US8399406B2 (pt)
EP (1) EP2438086B1 (pt)
JP (1) JP5666569B2 (pt)
KR (1) KR101668137B1 (pt)
CN (1) CN102459327B (pt)
AR (1) AR076973A1 (pt)
AU (1) AU2010256066B2 (pt)
BR (1) BRPI1010120B1 (pt)
CA (1) CA2764454C (pt)
CL (1) CL2011003003A1 (pt)
CO (1) CO6470858A2 (pt)
CY (1) CY1118676T1 (pt)
DK (1) DK2438086T3 (pt)
EA (1) EA021163B1 (pt)
ES (1) ES2621974T3 (pt)
GE (1) GEP20135967B (pt)
HR (1) HRP20170445T1 (pt)
HU (1) HUE034053T2 (pt)
IL (1) IL216718A (pt)
JO (1) JO3226B1 (pt)
LT (1) LT2438086T (pt)
MA (1) MA33374B1 (pt)
ME (1) ME01279B (pt)
MX (1) MX2011012951A (pt)
MY (1) MY159464A (pt)
NZ (1) NZ596848A (pt)
PE (1) PE20120541A1 (pt)
PL (1) PL2438086T3 (pt)
PT (1) PT2438086T (pt)
SG (1) SG176305A1 (pt)
SI (1) SI2438086T1 (pt)
TN (1) TN2011000558A1 (pt)
TW (1) TWI457132B (pt)
UA (1) UA103526C2 (pt)
WO (1) WO2010139442A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2170283B1 (en) 2007-06-22 2019-01-09 Board of Regents, The University of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
JP2014514275A (ja) * 2011-03-10 2014-06-19 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム タンパク質ナノ粒子分散系
US9815869B2 (en) 2012-02-09 2017-11-14 University Of Rochester SP-B and SP-C peptides, synthetic lung surfactants, and use thereof
RU2656185C2 (ru) 2012-11-21 2018-05-31 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Реконструированные сурфактанты легких
CN104382942A (zh) * 2014-11-05 2015-03-04 烟台东诚药业集团股份有限公司 一种猪肺表面活性物质混悬液制备新工艺
EP3106090A1 (en) 2015-06-15 2016-12-21 CHIESI FARMACEUTICI S.p.A. System for effective breath-synchronized delivery of medicament to the lungs
EP3285645B1 (en) 2015-04-22 2020-08-12 Chiesi Farmaceutici S.p.A. System for effective breath-synchronized delivery of medicament to the lungs
WO2016173634A1 (en) 2015-04-28 2016-11-03 Chiesi Farmaceutici S.P.A Device for facilitating the administration of a medicament to the lung by a catheter
EP3452041B1 (en) * 2016-03-07 2026-01-14 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Compositions and methods for administering ppar-gamma-agonists, surfactant peptides and phospholipids
CN109496159A (zh) 2016-07-28 2019-03-19 奇斯药制品公司 用于递送雾化药剂的方法和系统
MA46034A (fr) 2016-08-24 2021-04-28 Chiesi Farm Spa Formulation pharmaceutique stable comprenant une composition de surfactant pulmonaire reconstitué
AU2017349790A1 (en) 2016-10-26 2019-05-02 Chiesi Farmaceutici S.P.A. Device for facilitating the administration of a medicament to the lung by a catheter
JP7777392B2 (ja) 2016-12-22 2025-11-28 キエージ・フアルマチエウテイチ・エツセ・ピ・ア 進行性のｂｐｄの処置のための肺サーファクタント及びステロイドを含む処置的組み合わせ物
WO2019115771A1 (en) 2017-12-15 2019-06-20 Pari Pharma Gmbh Nebuliser system, holding system, combination comprising nebuliser system and holding system, and aerosol administration method
TW201927286A (zh) 2017-12-15 2019-07-16 義大利商凱西製藥公司 用於噴霧投藥之包含肺表面張力素的藥學調配物
MA52353A (fr) 2018-04-23 2021-04-28 Chiesi Farm Spa Combinaison thérapeutique comprenant un tensioactif pulmonaire et un stéroïde pour la prophylaxie de la dbp
EP3666315A1 (en) 2018-12-14 2020-06-17 PARI Pharma GmbH Aerosol delivery device and method of operating the aerosol delivery device
EP3666316A1 (en) 2018-12-14 2020-06-17 PARI Pharma GmbH Aerosol delivery device and method of operating the aerosol delivery device
EP3843105A1 (en) 2019-12-23 2021-06-30 PARI Pharma GmbH Control device for aerosol nebulizer system
WO2021151853A1 (en) 2020-01-28 2021-08-05 Chiesi Farmaceutici S.P.A. Polypeptides having improved properties
MX2024000058A (es) 2021-07-05 2024-02-23 Chiesi Farm Spa Proceso para la preparacion de un tensioactivo pulmonar.
EP4411745A1 (en) 2023-02-01 2024-08-07 Pari Medical Holding GmbH Medical evaluation method, aerosol nebulizer and medical evaluation system
EP4464354A1 (en) 2023-05-15 2024-11-20 Pari Medical Holding GmbH Method of operating an inhalation device, inhalation device and inhalation device system for providing inhalation process/breath guiding
EP4464236A1 (en) 2023-05-15 2024-11-20 Pari Medical Holding GmbH Method of operating an inhalation device, inhalation device and inhalation device system for providing inhalation process feedback
WO2025024609A1 (en) * 2023-07-25 2025-01-30 Biosuperior Technology, Inc. Polypeptides for lung surfactant compositions
WO2025245275A1 (en) * 2024-05-21 2025-11-27 Molecular Express, Inc. Surfactant preparations for pulmonary delivery, and methods for the preparation and use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1189625A1 (en) 1999-06-11 2002-03-27 Byk Gulden Lomberg Chemische Fabrik GmbH Pharmaceutical preparation containing modifications of surfactant protein b (sp-b) and surfactant protein c (sp-c)
ITMI20021058A1 (it) * 2002-05-17 2003-11-17 Chiesi Farma Spa Miscele di lipidi sintetici ottimizzate per la preparazione di un surfattante ricostituito
EP1481665A1 (en) * 2003-05-30 2004-12-01 CHIESI FARMACEUTICI S.p.A. Novel lipid mixtures for synthetic surfactants
CA2619079C (en) * 2005-05-11 2013-08-06 Yamasa Corporation Method of stabilizing pulmonary surfactant protein
EP2049554A4 (en) 2006-07-20 2011-06-29 Univ Rochester Medical Ct SYNTHETIC LUNG SURFAKTANT AND ITS USE
RS53172B (sr) 2006-10-13 2014-06-30 Chiesi Farmaceutici S.P.A. Rekonstituisani surfaktanti sa poboljšanim svojstvima
EP1997502A1 (en) * 2007-06-01 2008-12-03 CHIESI FARMACEUTICI S.p.A. Reconstituted surfactants having improved properties

Also Published As

Publication number Publication date
EA021163B1 (ru) 2015-04-30
EP2438086B1 (en) 2017-01-11
AU2010256066B2 (en) 2015-11-26
GEP20135967B (en) 2013-11-11
AU2010256066A1 (en) 2012-01-12
PE20120541A1 (es) 2012-05-12
JP2012528810A (ja) 2012-11-15
WO2010139442A1 (en) 2010-12-09
HRP20170445T1 (hr) 2017-05-19
KR20120028892A (ko) 2012-03-23
CN102459327B (zh) 2015-06-03
SI2438086T1 (sl) 2017-05-31
EP2438086A1 (en) 2012-04-11
SG176305A1 (en) 2012-01-30
JO3226B1 (ar) 2018-03-08
MA33374B1 (fr) 2012-06-01
US20110003733A1 (en) 2011-01-06
CA2764454A1 (en) 2010-12-09
EA201190292A1 (ru) 2012-06-29
CY1118676T1 (el) 2017-07-12
TN2011000558A1 (en) 2013-05-24
NZ596848A (en) 2013-06-28
AR076973A1 (es) 2011-07-20
MX2011012951A (es) 2011-12-16
CA2764454C (en) 2018-06-12
HUE034053T2 (en) 2018-01-29
CL2011003003A1 (es) 2012-05-18
JP5666569B2 (ja) 2015-02-12
BRPI1010120B1 (pt) 2022-12-06
CO6470858A2 (es) 2012-06-29
HK1166332A1 (en) 2012-10-26
CN102459327A (zh) 2012-05-16
PT2438086T (pt) 2017-04-18
TW201102083A (en) 2011-01-16
KR101668137B1 (ko) 2016-10-20
PL2438086T3 (pl) 2017-07-31
DK2438086T3 (en) 2017-04-10
IL216718A (en) 2016-08-31
ME01279B (me) 2013-06-20
ES2621974T3 (es) 2017-07-05
TWI457132B (zh) 2014-10-21
LT2438086T (lt) 2017-04-10
MY159464A (en) 2017-01-13
IL216718A0 (en) 2012-02-29
US8399406B2 (en) 2013-03-19
UA103526C2 (ru) 2013-10-25

Similar Documents

Publication Publication Date Title
BRPI1010120A2 (pt) composição de surfactante reconstituído melhorada contendo análogos de proteína b do surfactante (sp-b) e proteína c do surfactante ( sp-c)
BRPI0811320A2 (pt) Surfactantes reconstituídos com propriedades melhoradas
CO6400235A2 (es) Tensiactivos reconstituidos que tienen propiedades mejoradas
UA107571C2 (xx) Фармацевтична композиція
DK1877435T3 (da) Glucagon-lignende peptid 2 (GLP-2)-analoger
BR112015009486A2 (pt) surfactante reconstituído, formulação farmacêutica, kit e uso de surfactante reconstituído
BR112021020883A2 (pt) Formas sólidas de um inibidor de glyt1
CL2022001035A1 (es) Composiciones y métodos para minimizar la pérdida de proteínas a concentraciones de proteínas bajas
ATE503768T1 (de) Synthetische lungensurfactant peptide
EA202090802A1 (ru) Пептидная композиция для лечения повреждений, связанных с возбуждающей нейротоксичностью
WO2013054110A3 (en) Compositions for binding to amyloid proteins
ATE552271T1 (de) Antitumorarzneimittel, medikament, zusammensetzung und anwendung davon
MX2022003598A (es) Composicion farmaceutica, que comprende la proteina galectina 9 recombinante estabilizada, para la prevencion o el tratamiento de la artritis reumatoide y enfermedades oseas.
BR112014029856A2 (pt) formulação farmacêutica, métodos para determinar se células t reconhecem um polipeptídeo, para tratar um indivíduo contra alergia a alternaria e/ou cladosporium ou de prevenir em um indivíduo alergia a alternaria e/ou cladosporium, e para preparar uma formulação farmacêutica da invenção, uso de pelo menos três polipeptídeos ou sais, e, polipeptídeo ou sal
TH135738A (th) องค์ประกอบสารลดแรงตึงผิวที่ถูกสร้างใหม่ (reconstituted surfactant composition) ซึ่งถูกปรับปรุง ที่ประกอบด้วยแอนะล็อกส์ของโปรตีนของสารลดแรงตึงผิว b(sp-b) และโปรตีนของสารลดแรงตึงผิว c (sp-c)
DE602007009797D1 (de) Antitumorheilmittel, Medikament, Zusammensetzung und Verwendung davon
KR20130134530A (ko) Ｐｅａ―15 융합단백질을 포함하는 파킨슨병 예방 및 치료용 약학 조성물

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/05/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.